Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 15/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25340721 | 0.84 | NOTUM (0.43) | S1PR5S1PR1S1PR3S1PR4NOTUM | |
| SCHEMBL3284922 | 0.84 | NOTUM (0.43) | S1PR5S1PR1S1PR3S1PR4NOTUM | |
| SCHEMBL28389598 | 0.83 | ARG1 (0.35) | ARG1 | |
| SCHEMBL10179730 | 0.81 | SLC6A1 (0.47) | — | |
| SCHEMBL10179733 | 0.81 | SLC6A1 (0.47) | — | |
| SCHEMBL23855102 | 0.81 | SMN1; SMN2 (0.38) | ARG1 | |
| SCHEMBL25024449 | 0.79 | S1PR5 (0.40) | S1PR5S1PR1GRK5CDK8S1PR3 | |
| SCHEMBL20139634 | 0.79 | ARG1 (0.32) | S1PR1ARG1 | |
| Hydrochloric Acid SCHEMBL28336794 | 0.79 | SMN1; SMN2 (0.37) | ARG1 | |
| SCHEMBL3212052 | 0.79 | LMNA (0.41) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-20250188071-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2025-06-12 | — | — | US | disclosed |
| US-12258338-B2 | Modulators of the integrated stress response pathway | EVOTEC INTERNATIONAL GMBH (DE) | 2025-03-25 | — | — | US | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20220227747-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC (UK) LIMITED (GB) | 2022-07-21 | — | — | US | disclosed |
| CN-113993850-A | Modulators of integrated stress response pathways | 埃沃特克国际有限责任公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2020216766-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216766-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2020-10-29 | — | — | WO | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | S1PR5 973/4885S1PR1 896/4885GRK5 110/4885 |
| US-12258338-B2 | Modulators of the integrated stress response pathway | CRHR2, CRHR1, CRH | S1PR5 2203/4885S1PR1 2686/4885GRK5 90/4885 |
| US-20250188071-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | S1PR5 2203/4885S1PR1 2686/4885GRK5 90/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | S1PR5 955/4885S1PR1 857/4885GRK5 110/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | S1PR5 1775/4885S1PR1 1038/4885GRK5 408/4885 |
| US-20220227747-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | S1PR5 2203/4885S1PR1 2686/4885GRK5 90/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | S1PR5 2549/4885S1PR1 1940/4885GRK5 177/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | S1PR5 973/4885S1PR1 896/4885GRK5 110/4885 |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | S1PR5 2549/4885S1PR1 1940/4885GRK5 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.